Renaissance Capital logo

Turnstone Biologics Priced, Nasdaq: TSBX

Phase 1 biotech developing selected TIL therapies for solid tumors.

Industry: Health Care

Latest Trade: $3.12 +0.06 (+2.0%)

First Day Return: -8.3%

Return from IPO: -74.5%

Industry: Health Care

We are a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. We are developing next generation TIL therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. There are no TIL therapies that have received FDA approval to date. To our knowledge, at present there are no therapies in clinical development that provide curative outcomes for the majority of patients in our chosen solid tumor indications. Our innovative Selected TIL approach focuses on selecting and expanding the most potent tumor-reactive T cells to overcome the limitations of bulk TILs. This approach expands upon work conducted in academia that demonstrated improved clinical responses for certain selected TILs in solid-tumor types where bulk TILs have not shown clinical benefit. We are leveraging this work to establish a standardized manufacturing process for large scale production of our Selected TILs.
more less
IPO Data
IPO File Date 06/12/2023
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.7
Deal Size ($mm) $80
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/20/2023
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.7
Deal Size ($mm) $80
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Leerink Partners
more
Company Data
Headquarters La Jolla, CA, United States
Founded 2015
Employees 108
Website www.turnstonebio.com

Turnstone Biologics (TSBX) Performance